Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Asian Pac J Cancer Prev. 2013;14(11):6351-6.

The Kampo medicine Goshajinkigan prevents neuropathy in breast cancer patients treated with docetaxel.

Author information

  • 1Breast Center, Bell Land General Hospital, Japan E-mail : abe@belle.shiga-med.ac.jp.



Goshajinkigan (GJG) is used for the treatment of several neurological symptoms. We investigated the efficacy of GJG and mecobalamin (B12) against neurotoxicity associated with docetaxel (DOC) in breast cancer patients.


Sixty breast cancer patients were treated with DOC. Thirty-three patients (GJG group) received oral administration of 7.5 g/day GJG and 27 patients (B12 group) received oral administration of 1500 μg/day B12. Neuropathy was evaluated according to DEB-NTC (Neurotoxicity Criteria of Debiopharm), Common Terminology Criteria for Adverse Events (NCI-CTC) ver. 3.0, and a visual analogue scale (VAS). This study employed a randomized open design.


The incidence of neuropathy was 39.3% in the GJG group, and 88.9% in the B12 group (p<0.01). In the GJG group, grade 1 DEB-NTC was observed in 2 cases, grade 2 in 5 cases and grade 3 in 5 cases. Grade 1 NCI-CTC was observed in 7 cases, grade 2 in 6 cases, and VAS was 2.7 ± 2.2. In the B12 group, grades 1, 2 and 3 DEB-NTC were observed in one case, 12 cases and 12 cases, respectively; and grades 1, 2 and 3 NCI-CTC were observed in 11 cases, 12 cases and one case, and VAS was 4.9 ± 2.4.


Concomitant administration of GJG is useful in preventing neuropathy in breast cancer patients treated with a DOC regimen.

[PubMed - in process]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Asian Pacific Organization for Cancer Prevention
    Loading ...
    Write to the Help Desk